Fusion Antibodies PLC
LSE:FAB
Fusion Antibodies PLC
LSE:FAB
Price:
3.4 GBX
Market Closed
Updated:
May 13, 2024
Fusion Antibodies PLC
Total Liabilities & Equity
|
Fusion Antibodies PLC
Total Liabilities & Equity Peer Comparison
Comparables:
ONT
O
ORPH
DXRX
ERGO
HVO
Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Fusion Antibodies PLC
LSE:FAB
|
Total Liabilities & Equity
£2.1m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Total Liabilities & Equity
£777.1m
|
CAGR 3-Years
40%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
O
|
Open Orphan PLC
LSE:ORPH
|
Total Liabilities & Equity
£51.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Diaceutics PLC
LSE:DXRX
|
Total Liabilities & Equity
£48.3m
|
CAGR 3-Years
29%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
|
Ergomed PLC
LSE:ERGO
|
Total Liabilities & Equity
£133.5m
|
CAGR 3-Years
16%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
hVIVO PLC
LSE:HVO
|
Total Liabilities & Equity
£83.2m
|
CAGR 3-Years
20%
|
CAGR 5-Years
61%
|
CAGR 10-Years
43%
|
See Also
What is Fusion Antibodies PLC's Total Liabilities & Equity?
Total Liabilities & Equity
2.1m
GBP
2.1m
GBP
Based on the financial report for Sep 30, 2023, Fusion Antibodies PLC's Total Liabilities & Equity amounts to 2.1m GBP.
What is Fusion Antibodies PLC's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
-20%
-20%
Over the last year, the Total Liabilities & Equity growth was -48%. The average annual Total Liabilities & Equity growth rates for Fusion Antibodies PLC have been -37% over the past three years , -20% over the past five years .
You don't have any saved screeners yet
